Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease

The goal of this observational study, drug-free, cross-sectional, single-center is to describe the incidence and characteristics of the clinical course and any short- and medium-term complications of patients with congenital heart disease of medical interest, and pediatric patients with cardiomyopathy, arrhythmic pathology or pulmonary arterial hypertension who have been affected by Sars-Cov-2 disease. The secondary objective of the study is to identify risk factors for the development of moderate-severe forms of COVID-19 disease in the study population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Congenital Heart Disease COVID-19 Cardiomyopathies Cardiomyopathy Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Coronaviridae Infections Coronavirus Infections Heart Defects, Congenital Heart Diseases Hypertension, Pulmonary Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral Pulmonary Arterial Hypertension RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections SARS CoV-2 Infection Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, 40138, Italy

About this study

This is an observational, drug-free, cross-sectional, single-centre study. All patients followed at our centre and suffering from congenital heart disease treated with only haemodynamic procedures haemodynamic procedures alone, as well as paediatric patients suffering from cardiomyopathy, pulmonary hypertension or arrhythmic pathology whose follow-up was still in progress at the time of the start of the pandemic (due to death or for reasonsof the patient). The structural collection of data necessary for the evaluation of targets will take place through the creation of a specific electronic archive, in which census of all patients who have undergone follow-up at our centre since 01/01/2005 at the time of study approval and still in follow-up at the time of the start of the pandemic.

Patients of all ages will be enrolled age, both paediatric and adult, followed at our centre. It is estimated to include in the study approximately 5000 patients.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients of all ages with congenital heart disease undergoing hemodynamic procedures at our center or in natural history
Pediatric patients with cardiomyopathy, arrhythmic disease, or hypertension pulmonary
Obtaining informed consent
Patients who have access to an e-mail address and a computer to complete the questionnaire

Exclusion criteria

Patients with congenital heart disease undergoing corrective or palliative surgical treatment

Treatment and study plan

Primary outcomes

Severity of SARS-CoV-2 infection evaluation

Time frame: Upon completion of the questionnaire by patient on day 1
The presence of ongoing SARS-CoV-2 infection will be defined as detection of viral RNA to a molecular swab or the detection of specific antigen at an antigenic swab, while the presence of previous infection will be defined as the presence of seroconversion for SARS-CoV-2 at a quantitative serological test. Severity of SARS-CoV-2 infection will be defined at different forms:
- Severe form: Admission to intensive care unit, need for invasive respiratory support, death
- Moderate form: Need for hospitalization or home oxygen therapy, or Worsening of oxygen dependence in patients on chronic home oxygen therapy.
- Mild form: Symptomatic patients who do not meet the criteria for moderate or severe disease.
- Asymptomatic form: Patients with infection positivity who do not have symptoms of disease.
The patients' medical history and clinical data, as reported in the questionnaire, will be evaluated to look for possible risk factors for the development of severe forms of COVID-19 disease.

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Official study title

Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease Not Treated Surgically, and in a Population of Pediatric Patients With Cardiomyopathy, Arrhythmic Pathology, or Pulmonary Hypertension

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2021
First posted: Jan 20, 2025
Registry last updated: Jan 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed